Evidence map›Paper›PMID 38751786›Full record

ArticleFrontiers in pharmacology2024

Development and therapeutic evaluation of 5D3(CC-MLN8237)

Ioanna Liatsou, Betelhem Assefa, Wathsala Liyanage, Sharmane Surasinghe, Zora Nováková, Cyril Bařinka, Kathleen Gabrielson, Venu Raman, Dmitri Artemov, Sudath Hapuarachchige

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ioanna LiatsouDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Betelhem AssefaDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Wathsala LiyanageDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Sharmane SurasingheDepartment of Neuroscience, Johns Hopkins University, Baltimore, MD, United States.
Zora NovákováLaboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czechia.
Cyril BařinkaLaboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czechia.
Kathleen GabrielsonDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Venu RamanDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Dmitri ArtemovDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Sudath HapuarachchigeDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is an aggressive cancer that can progress rapidly and eventually become castrate-resistant prostate cancer (CRPC). Stage IV metastatic castrate-resistant prostate cancer (mCRPC) is an incurable late-stage cancer type with a low 5-year overall survival rate. Targeted therapeutics such as antibody-drug conjugates (ADCs) based on high-affinity monoclonal antibodies and potent drugs conjugated via smart linkers are being developed for PC management. Conjugating further with

Indexed as

antibody-theranostic conjugatesAurora A kinase inhibitionimage-guided drug deliveryMLN8237prostate cancerPSMA -prostate-specific membrane antigentargeted therapytheranostics

Identifiers

PMID38751786
PMCPMC11094276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.